Summarized by Masters of Longevity from PR Newswire.
This article previews clinical trial coverage of protein-based combination respiratory vaccines for older adults, focusing on immunogenicity and tolerability data and development implications.
Key Takeaways
- A randomized Phase 2 trial in older adults compared two combination protein vaccines against placebo and showed generally higher antibody GMTs at 28 days.
- Vaccine groups experienced approximately a 62% lower rate of reported respiratory tract infections versus placebo within 28 days post-vaccination.
- SCB-1022 and SCB-1033 were generally well tolerated with mostly mild, transient local and systemic adverse events lasting about two days.
